Trials / Withdrawn
WithdrawnNCT01419704
Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Talaris Therapeutics Inc. · Industry
- Sex
- All
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this research study is to establish chimerism and avoid graft-versus-host disease in patients with hemoglobinopathies.
Detailed description
This proposal is a phase I/II feasibility study to demonstrate that mixed chimerism can be established with minimal risk in recipients with hemoglobinopathies treated with Campath-1H-based nonmyeloablative conditioning and graft engineering to reduce the risk of Graft Versus Host Disease (GVHD), but preserve engraftment of donor cells.
Conditions
- Anemia, Sickle Cell
- Complex and Transfusion-dependent Hemoglobinopathies
- Thalassemia
- Diamond-Blackfan Anemia
- Bone Marrow Failure Syndromes
- Alpha-Thalassemia
- Beta-Thalassemia
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Enriched Hematopoetic Stem Cell Infusion | Enriched Hematopoetic Stem Cell Infusion |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2016-05-01
- Completion
- 2016-05-01
- First posted
- 2011-08-18
- Last updated
- 2023-03-03
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01419704. Inclusion in this directory is not an endorsement.